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Theneuropeptide galanin has been shown to interactwith the opioid system.More specifically, galanin counteracts the behavioral effects
of the systemic administration of-opioid receptor (MOR) agonists. Yet themechanism responsible for this galanin–opioid interaction
has remained elusive. Using biophysical techniques inmammalian transfected cells, we found evidence for selective heteromerization of
MOR and the galanin receptor subtype Gal1 (Gal1R). Also in transfected cells, a synthetic peptide selectively disrupted MOR–Gal1R
heteromerization as well as specific interactions between MOR and Gal1R ligands: a negative cross talk, by which galanin counteracted
MAPK activation induced by the endogenous MOR agonist endomorphin-1, and a cross-antagonism, by which a MOR antagonist coun-
teractedMAPK activation induced by galanin. These specific interactions, which represented biochemical properties of the MOR-Gal1R
heteromer, could then be identified in situ in slices of rat ventral tegmental area (VTA) with MAPK activation and two additional cell
signalingpathways,AKTandCREBphosphorylation. Furthermore, in vivomicrodialysis experiments showed that thedisruptivepeptide
selectively counteracted the ability of galanin to block the dendritic dopamine release in the rat VTA induced by local infusion of
endomorphin-1, demonstrating a key role ofMOR-Gal1R heteromers localized in the VTA in the direct control of dopamine cell function
and their ability tomediate antagonistic interactions betweenMOR andGal1R ligands. The results also indicate thatMOR-Gal1R hetero-
mers should be viewed as targets for the treatment of opioid use disorders.
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Introduction
Opioid use disorders constitute a renewed societal problem with
an increasing demand of alternatives to the prevalent substitu-
tion therapy with opioid receptor ligands. The-opioid receptor
(MOR) is essential for the analgesic and reinforcing effects of
opioids (Matthes et al., 1996). It is well established that MOR
localized in the striatum and in the ventral midbrain are involved
in the reinforcing effects of opioids (Wise, 1989; McBride et al.,
1999; Zangen et al., 2002; Jhou et al., 2012). In the ventral mid-
brain, endogenous and exogenous MOR agonists activate dopa-
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Significance Statement
The -opioid receptor (MOR) localized in the ventral tegmental area (VTA) plays a key role in the reinforcing and addictive
properties of opioids.With parallel in vitro experiments inmammalian transfected cells and in situ and in vivo experiments in rat
VTA, we demonstrate that a significant population of these MORs form functional heteromers with the galanin receptor subtype
Gal1 (Gal1R), which modulate the activity of the VTA dopaminergic neurons. The MOR-Gal1R heteromer can explain previous
results showing antagonistic galanin–opioid interactions and offers a new therapeutic target for the treatment of opioid use
disorder.
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minergic cells in the ventral tegmental area (VTA), which
depends primarily on a local MOR-mediated inhibition of tonic
GABAergic neurotransmission (Spanagel et al., 1992; Chefer et
al., 2009; Barrot et al., 2012; Cui et al., 2014; Matsui et al., 2014)
and also possibly on a direct activation of MOR localized on
dopaminergic cells that activate voltage-dependent calcium
channels (Margolis et al., 2014).
A number of neuropeptides, such as orexin, neuopeptide Y,
melanocyte stimulating hormone, and galanin, provide internal
signals that are integrated in the brain homeostatic center, the
hypothalamus, to regulate the learning and elicitation of food-
associated behaviors. This is not only related to their indirect
influence on the ascending dopaminergic system, conveyed by
the large lateral hypothalamic efferent connection to the VTA
(Faget et al., 2016), but also by their direct influence on neuro-
peptide receptors localized in the soma and/or dendrites of the
dopaminergic cells or in the terminals of their excitatory or in-
hibitory afferents (Palmiter, 2007; Volkow et al., 2011). This pro-
vides the frame for the overlap in the mechanisms involved in
substance use disorders and loss of control of food intake and for
introducing neuropeptide receptors as targets for both condi-
tions (Palmiter, 2007; Volkow et al., 2011; DiLeone et al., 2012;
Boughton and Murphy, 2013).
Several studies indicate the existence of antagonistic interac-
tions between the galanin and opioid systems. Central infusion of
galanin attenuates morphine place preference (Zachariou et al.,
1999). Furthermore, galanin knock-out mice demonstrate in-
creased locomotion and place preference after acute morphine
administration and increased signs of opioid withdrawal after
repeated morphine administration, which is counteracted by the
systemic administration of the nonpeptidergic, nonselective gala-
nin receptor agonist galnon (Zachariou et al., 2003; Hawes et al.,
2008). In addition, genetic studies have found associations of
galanin gene polymorphisms with susceptibility to opioid use
disorder (Levran et al., 2008; Beer et al., 2013). The most signifi-
cant association was observed for the single nucleotide polymor-
phism rs948854, localized in the promoter region (Beer et al.,
2013).
Three galanin receptor subtypes so far have been identified:
Gal1, Gal2, and Gal3 (Gal1R, Gal2R, and Gal3R). Gal1R and
Gal2R are the most widespread in the brain, but the lack of spe-
cific antibodies and ligands preclude their precise neuronal local-
ization (Hawes and Picciotto, 2005; Lang et al., 2015). It has
therefore been difficult to unequivocally establish the localization
of galanin receptors and the receptormechanisms controlling the
effects of opioids (Picciotto, 2008). Based on the reported ability
of galanin to control MOR-mediated signaling in the VTA
(Hawes et al., 2008) and the well established localization ofMOR
and possible localization of galanin receptors in the VTA (Pic-
ciotto, 2008), the present study aimed at evaluating the existence
of direct intermolecular and functional interactions between
MOR and galanin receptors in the VTA that could locally control
dopamine cell function. We first demonstrate that MOR hetero-
merizes with Gal1R in mammalian transfected cells, and we dis-
close specific biochemical properties of the heteromer by using a
synthetic peptide that selectively disrupts MOR–Gal1R hetero-
merization. MOR-Gal1R heteromers in the VTA could then be
demonstrated by identification of the same biochemical proper-
ties in situ, with their ability to influence several signaling path-
ways. More importantly, the use of the disruptive peptide with in
vivomicrodialysis experiments allowed demonstrating a key role
of MOR-Gal1R heteromers localized in the VTA in the direct
control of dopamine cell function and their ability to mediate
antagonistic interactions between MOR and Gal1R ligands.
Materials andMethods
Expression vectors and fusion proteins. For bioluminescence resonance
energy transfer (BRET) experiments, to obtain receptors fused to Renilla
luciferase (Rluc) or to yellow fluorescence protein (YFP), human cDNAs
for MOR, Gal1R, Gal2R, GABAB2 receptor (GABAB2R), or serotonin
5HT2B receptor (5HT2BR) cloned into pcDNA3.1 were amplified with-
out their stop codons using sense and antisense primers harboring the
following: EcoRI and BamHI sites to clone 5HT2BR and EcoRV and
KpnI sites to clone MOR in pcRLuc-N1 vector (pRLuc-N1; PerkinEl-
mer); EcoRI and KpnI or BamHI sites to clone Gal1R or GABAB2R,
respectively, in pEYFP-N1 vector (enhanced yellow variant of GFP;
Clontech); and HindIII and KpnI sites to clone Gal2R in pEYFP-N1
vector. Amplified fragments were subcloned to be in-frame with restric-
tion sites of pRLuc-N1 or pEYFP-N1 vectors to provide plasmids that
express proteins fused toRluc or YFPon theC-terminal end (MOR-Rluc,
5HT2BR-Rluc, Gal1R-YFP, Gal2R-YFP, or GABAB2R-YFP). For bimo-
lecular fluorescence complementation (BiFC) experiments, sequences
encoding amino acid residues 1–155 and 156–238 of theVenus variant of
YFP were subcloned in pcDNA3.1 vector to obtain complementary Ve-
nus hemitruncated proteins. Then human cDNA for MOR was sub-
cloned into pcDNA3.1-nYFP to provide a plasmid that expresses the
receptor fused to the hemitruncated nVenus-YFP on the C-terminal end
of the receptor (MOR-nYFP), and human cDNA for Gal1R and Gal2R
was also subcloned into pcDNA3.1-cYFP to provide a plasmid that ex-
presses the receptor fused to the hemitruncated cVenus-YFP on the
C-terminal end of the receptor (Gal1R-cYFP, Gal2R-cYFP).
TAT-TM peptides. Peptides, with the sequence of transmembrane (TM)
domains of a G-protein-coupled receptor (GPCR) fused to the cell-
penetratingHIV transactivator of transcription (TAT) peptide, were used as
heteromer-disrupting agents. TAT-TM peptides can be inserted effectively
into the plasmamembrane as a result of both the penetration capacity of the
TAT peptide and the hydrophobic property of the TM domain (He et al.,
2011). To obtain the right orientation of the inserted peptide, TM1, TM5,
andTM7ofMORwere synthesizedwith theTATsequence localized in theC
terminusof the correspondingTM(GenemedSynthesis). Peptide sequences
for MOR TAT-TM1, MOR TAT-TM5, and MOR TAT-TM7 were
MVTAITIMALYSIVCVVGLFGNFLVMYVIVYGRKKRRQRRR, CVFI
FAFIMPVLIITVCYGLMILGRKKRRQRRR, and TFQTVSWHFCIAL
GYTNGRKKRRQRRR, respectively.
Cell culture and transient transfection. Human embryonic kidney
(HEK-293T) cells obtained from ATCC were grown in DMEM (Life
Technologies) supplemented with 2mM L-glutamine, 100g/ml sodium
pyruvate, 100 U/ml penicillin/streptomycin, MEM nonessential amino
acid solution (1:100), and 5% (v/v) heat-inactivated fetal bovine serum
(all supplementswere from Invitrogen). Cells weremaintained at 37°C in
an atmosphere of 5% CO2. Cells growing in six-well dishes were tran-
siently transfected with the corresponding fusion protein cDNA by the
polyethylenimine (PEI; Sigma) method and were incubated (4 h) with
the corresponding cDNA together with PEI (5 ml/mg cDNA of 10 mM
PEI) and 150 mM NaCl in a serum-starved medium. After 4 h, the me-
dium was changed to a fresh complete culture medium. Forty-eight
hours after transfection, cells were washed twice in quick succession in
HBSS [containing the following (in mM): 137 NaCl, 5 KCl, 0.34
Na2HPO4 12 H2O, 0.44 KH2PO4, 1.26 CaCl2 2 H2O, 0.4 MgSO4
7 H2O, 0.5 MgCl2, and 10 HEPES, pH 7.4], supplemented with 0.1%
glucose (w/v), detached, and resuspended in the same buffer. The cell
numberwas controlled by determining the sample protein concentration
using a Bradford assay kit (Bio-Rad) with bovine serum albumin (BSA)
dilutions as standards.
BiFC. After 48 h, HEK-293T cells transiently cotransfected with the
cDNA encoding for the receptor fused to nYFP and the receptor fused to
cYFPwere treated or not with the indicated TAT-TMpeptides (4M) for
4 h at 37°C. Reconstituted YFP expression was quantified by distributing
the cells (20 g of protein) in 96-well microplates (black plates with a
transparent bottom; Porvair), and emission fluorescence at 530 nm was
read in a Fluo Star Optima Fluorimeter (BMG Labtech) equipped with a
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Figure 1. Gal1R-MOR heteromers in transfected HEK-293T cells. A, Confocal microscopy images of HEK-293T cells transfected with MOR-Rluc cDNA (0.5 g) and Gal1R-YFP or
Gal2R-YFP cDNA (1g). YFP-fused proteins were identified by their own fluorescence (green) and MOR-Rluc by immunocytochemistry (red). Colocalization is shown in yellow (merge).
Scale bars, 20m. B, ERK1/2 phosphorylation in cells transfected with MOR, MOR-Rluc, or MOR-nYFP cDNA (1g) and treated with endomorphin-1 (100 nM) or cells transfected with
Gal1R, Gal1R-YFP, or Gal1R-cYFP cDNA (1g) or Gal2R, Gal2R-YFP, or Gal2R-cYFP cDNA (1.2g) and treated with galanin (100 nM). Values are expressed as means SEM (n 4) of
the percentage of values in cells expressing nonfused receptors; top, representative Western blots. C, BRET saturation experiments in cells transfected with MOR-Rluc cDNA (0.8g) and
increasing amounts of Gal1R-YFP cDNA (0.5–7g, red curve) or Gal2R-YFP cDNA (0.2– 4g, black line) or, as negative controls, with MOR-Rluc cDNA (0.8g) and increasing amounts
of GABAB2R-YFP cDNA (0.3–3g, green line) or with serotonin 5-HT2BR-Rluc cDNA (1g) and increasing amounts of Gal1R-YFP cDNA (0.5–5g, blue line). The relative amount of BRET
is obtained as a function of 100 times the ratio between the fluorescence of the acceptor (YFP) and the luciferase activity of the donor (Rluc). BRET is expressed as milliBRET units and is
expressed as the mean SD (n 3– 6) grouped as a function of the amount of BRET acceptor. D, Fluorescence complementation experiments in cells transfected with Gal1R-cYFP and
MOR-nYFP, Gal2R-cYFP and MOR-nYFP, Gal1R-cYFP and nonfused nYFP, or nonfused cYFP and MOR-nYFP cDNA (4g in all cases). Values are expressed as means SEM (n 3– 6) of
the percentage of values in cells not expressing Gal1R (100%: 15,000 fluorescence units). E, Fluorescence complementation experiments in cells transfected with Gal1R-cYFP and
MOR-nYFP cDNA (4g) and increasing amounts (0 – 8g) of nonfused Gal1R cDNA. Values are expressed as means SEM (n 3– 6) of the percentage of values in cells not expressing
Gal1R (100%: 15,000 fluorescence units). F, Fluorescence complementation experiments in cells transfected with Gal1R-cYFP andMOR-nYFP cDNA (4g) and incubated for 4 h with MOR
TAT-TM1, MOR TAT-TM5, or MOR TAT-TM7 peptides (4M) or with medium (M). Values are expressed as means SEM (n 3– 6) of the percentage of fluorescence in untreated cells
(100%: 15,000 fluorescence units). Statistical differences in D–F were analyzed by one-way ANOVA followed by Newman–Keuls multiple comparison tests; *p 0.05 and ***p 0.001,
compared with cells expressing Gal1R-cYFP and MOR-nYFP, in the absence of nonfused Gal1R or without incubation with TAT peptides.
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high-energy xenon flash lamp, using a 10 nm bandwidth excitation filter
at 400 nm reading. Protein fluorescence expression was determined as
the fluorescence of the sample minus the fluorescence of cells not ex-
pressing the fusion proteins (basal). Cells expressing Gal1R-cYFP and
nYFP or MOR-nYFP and cYFP showed similar fluorescence levels to
nontransfected cells.
BRET.HEK-293T cells were transiently cotransfected with a constant
amount of expression vector encoding for receptor fused to Rluc and
with increasing amounts of the expression vector corresponding to re-
ceptor fused to YFP. Protein–YFP expression was quantified by distrib-
uting cells (20 g of protein, around 4000 cells/well) in 96-well
microplates (black plates with a transparent bottom), and fluorescence
was read in a Fluo Star Optima Fluorimeter (BMG Labtech), equipped
with a high-energy xenon flash lamp, using a 10 nmbandwidth excitation
filter at 400 nm reading. Protein fluorescence expression was determined
as the fluorescence of the sample minus the fluorescence of cells express-
ing the receptor–Rluc alone. For BRET measurements, the equivalent of
20 g of cell suspension were distributed in 96-well microplates (Corn-
ing 3600, white plates; Sigma) and 5 M coelenterazine H (Invitrogen)
was added. After 1 min, readings were collected using a Mithras LB 940
late reader (Berthold Technologies) that allows the integration of the
signals detected in the short-wavelength filter at 485 nm (440–500 nm)
and the long-wavelength filter at 530 nm (510–590 nm). To quantify
receptor–Rluc expression, luminescence readings were also performed
after 10 min of adding 5 M coelenterazine H. Fluorescence and lumi-
nescence of each sample were measured before every experiment to con-
firm similar donor expressions (100,000 bioluminescence units) while
monitoring the increase in acceptor expression (1000–40,000 fluores-
cence units). The net BRETwas defined as [(long-wavelength emission)/
(short-wavelength emission)]-cf., where cf. corresponds to [(long-
wavelength emission)/(short-wavelength emission)] for the receptor–
Rluc expressed alone in the same experiment. BRET is expressed as
milliBRET units (mBU; net BRET 1000). Data were fitted to a nonlin-
ear regression equation, assuming a single-phase saturation curve with
GraphPad Prism software.
Immunodetection assays.Cells were fixed in 4% paraformaldehyde for 15
minandwashedwithPBScontaining20mMglycine (bufferA) toquench the
aldehyde groups. After permeabilizationwith buffer A containing 0.2%Tri-
tonX-100 for 5min, cellswere treatedwithPBS containing 1%ofBSA.After
1 h at room temperature, cells were labeled with the primarymousemono-
clonal anti-RLuc receptor antibody (1:200; Millipore) for 1 h to detect
MOR–Rluc, washed, and stained with the secondary Cy3 donkey anti-
mouse antibody (1:200; Jackson ImmunoRe-
search).Gal1RorGal2R fused toYFPproteinwas
detected by its fluorescence properties. The sam-
ples were rinsed several times andmounted with
a medium suitable for immunofluorescence
(30% Mowiol; Calbiochem). Samples were ob-
served in a Leica SP2 confocal microscope.
Rat VTA slices preparation. Male Sprague
Dawley rats (2 months old; animal facility of
the Faculty of Biology, University of Barce-
lona) were used. The animals were housed two
per cage and kept on a 12 h dark/light cycle
with food and water available ad libitum, and
experiments were performed during the light
cycle. All procedures were approved by the
Catalan Ethical Committee for Animal Use
(CEAA/DMAH 4049 and 5664). Animals were
killed by decapitation under 4% isoflurane an-
esthesia, and brains were rapidly removed,
placed in ice-cold oxygenated (O2/CO2, 95%/
5%) Krebs–HCO3
 buffer (in mM: 124 NaCl, 4
KCl, 1.25 KH2PO4, 1.5 MgCl2, 1.5 CaCl2, 10
glucose, and 26NaHCO3, pH7.4), and sliced at
4°C using a brain matrix (Zivic Instruments).
VTA slices (500 m thick) were dissected at
4°C in Krebs–HCO3
 buffer; each slice was
transferred into a 12-well plate with Corning
Netwell inserts containing 2 ml of ice-cold
Krebs–HCO3
 buffer. The temperature was raised to 23°C, and after 30
min, the mediumwas replaced by 2ml of fresh buffer (23°C). Slices were
incubated under constant oxygenation (O2/CO2, 95%/5%) at 30°C for
4 h in an Eppendorf Thermomixer (5 PRIME), and the medium was
replaced by fresh buffer and incubated for 30 min before the addition of
any agent. After incubation, the solution was discarded, and slices were
frozen on dry ice and stored at80°C until ERK1/2 phosphorylationwas
determined.
Determination of phosphorylated ERK1/2, AKT, and CREB in cells or in
VTA tissue. Transfected HEK-293T cells were cultured in serum-free
medium for 16 h before the addition of any agent. Cells or rat VTA slices
were treated or not with the indicated ligands for the indicated time and
were lysed by the addition of 300 l of ice-cold lysis buffer (50 mM
Tris-HCl, pH7.4, 50mMNaF, 150mMNaCl, 45mM-glycerophosphate,
1% Triton X-100, 20 M phenyl-arsine oxide, 0.4 mM NaVO4, and pro-
tease inhibitor mixture). Cellular debris was removed by centrifugation
at 13,000  g for 5 min at 4°C, and the protein was quantified by the
bicinchoninic acid method using BSA dilutions as standard. Phosphor-
ylated proteins were then determined by Western blot, using a mouse
anti-phospho-ERK1/2 antibody (1:2500; Sigma) and rabbit anti-total-
ERK1/2 antibody (1: 40,000; Sigma) to quantify phospho-ERK1/2 or a
rabbit anti-phospho-Ser473-AKT antibody (1:2500; SAB Signalway An-
tibody) and amouse anti-total-AKT antibody (1:2500; Cell Signaling) to
quantify phospho-AKT or a rabbit anti-phospho-CREB antibody (1:
1000; Abcam) and a mouse anti-total-CREB antibody (1:2000; Milli-
pore) to quantify phosphor-CREB. Bandswere visualized by the addition
of a mixture of IRDye 800 (anti-mouse) antibody (1:10,000; Sigma) and
IRDye 680 (anti-rabbit) antibody (1:10,000; Sigma) and scanned by an
Odyssey infrared scanner (LI-COR Biosciences). Band densities were
quantified using the scanner software exported to Excel (Microsoft). The
level of phosphorylated proteins was normalized for differences in load-
ing using the total (phosphorylated plus nonphosphorylated) protein
band intensities.
In vivomicrodialysis experiments.Male SpragueDawley rats (3months
old; Charles River Laboratories) were used. Animals were housed two per
cage and kept on a 12 h dark/light cycle with food and water available ad
libitum. Experiments were performed during the light cycle. All animals
used in the study were maintained in accordance with the National In-
stitutes of Health Guide for the Care and Use of Laboratory Animals, and
the animal research conducted to perform this study was reviewed and
approved by the NIDA Intramural Research Program Animal Care and
Figure 2. Selectivity of Gal1R and MOR ligands. ERK1/2 phosphorylation was determined in HEK-293T cells transfected with
MOR-Rluc cDNA (A; 1.2 g) or with Gal1R-YFP cDNA (B; 2 g). Cells were preincubated for 20 min with medium, the MOR
antagonist CTOP (10M), or the Gal1R antagonist M40 (10M) and treated for 12 min with medium, galanin (Gal, 100 nM), or
endomorphin-1 (End-1, 100 nM); top, representative Western blots. Values are expressed as means  SEM (n  4) of the
percentage of values in untreated cells (dotted lines). Statistical differences were analyzed by one-way ANOVA followed by
Newman–Keuls multiple comparison tests; ***p 0.001 and ###p 0.001, compared with untreated cells or with cells treated
with the corresponding agonist alone, respectively.
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Use Committee (protocol number 15-BNRB-73). Rats were deeply anes-
thetized with 3ml/kg Equithesin (4.44 g of chloral hydrate, 0.972 g of Na
pentobarbital, 2.124 g of MgSO4 44.4 ml of propylene glycol, 12 ml of
ethanol, and distilled H2O up to 100 ml of the final solution; NIDA
Pharmacy) and implanted unilaterally in the ventral tegmental area (co-
ordinates in millimeters from bregma with a 10° angle in the coronal plane:
anterior,5.6; lateral, 2.4; vertical,9) with a specially designed microdi-
alysis probe that allows the direct infusion of large peptides within the sam-
plingarea (Navarroetal., 2015).After surgery, ratswereallowedtorecover in
hemispherical CMA-120 cages (CMA Microdialysis) equipped with two-
channel overhead fluid swivels (Instech) connected to a sample collector
(CMA 470, CMA). Twenty-four hours after implanting the probe, experi-
ments were performed on freely moving rats in the same hemispherical
home cages in which they recovered overnight from surgery. An artificial
cerebrospinal solution containing (inmM)144NaCl, 4.8KCl, 1.7CaCl2, and
1.2 MgCl2 was pumped through the probe at a constant rate of 1 l/min.
After awashout period of 90min, dialysate sampleswere collected at 20min
intervals. Forpeptide infusion, galanin and endopmorphin-1weredissolved
in ACSF to a final concentration of 10M, whereas TAT-TM peptides were
dissolved in 0.1% DMSO in ACSF to a final concentration of 60 M. All
peptides were injected with a 1l syringe (Hamilton) driven by an infusion
pump and coupledwith silica tubing (73m inner diameter; Polymicro) to
the microdialysis probe infusion port (dead volume, 40 nl), which was
primed with ACSF and plugged during implantation. All peptides were de-
livered at a rate of 16.6 nl/min. At the end of the experiment, rats were given
an overdose of Equithesin, the brains were extracted and fixed in formalde-
hyde, and probe placement was verified using cresyl violet staining. Dopa-
mine content was measured by HPLC coupled with a coulometric detector
(5200a Coulochem III; ESA).
Statistics. Parametric statistics (one-way or repeated-measures
ANOVA followed by Newman–Keuls multiple comparison tests) were
used, since the different groups analyzed showed normality and homo-
geneity of variance. GraphPad Prism software version 5 was used for the
statistical analysis.
Results
Gal1R but not Gal2R forms heteromers withMOR in
transfected mammalian cells
The possibility of intermolecular interactions betweenGal1R and
Gal2R with MOR was first investigated with a BRET assay, using
receptors fused to Rluc or to YFP. These fusion proteins properly
trafficked to the cell membrane of transfected HEK-293T cells,
and practically all transfected cells showed cotransfection, as
shown by confocal microscopy (Fig. 1A). Fusion proteins were
fully functional, as found by comparing their ability to increase
ERK1/2 phosphorylation with that of native receptors (Fig. 1B).
Although MOR highly colocalized with Gal1R or Gal2R when
coexpressed in HEK-293T cells (Fig. 1A), saturable BRET curves
were only obtained in cells transfected with a constant amount of
MOR-Rluc cDNA and increasing amounts of Gal1R-YFP cDNA
(Fig. 1C; with BRETmax and BRET50 values of 47.5 3 mBU and
6.2  1.6, respectively). In contrast, linear plots were obtained
in cells transfected with a constant amount of MOR-Rluc and
increasing amounts of Gal2R-YFP cDNA, similar to the nega-
tive controls; cells transfected with a constant amount of MOR-
Rluc cDNA and increasing amounts of GABAB2-YFP receptor
Figure 3. Negative cross talk within the Gal1R-MOR heteromer. ERK1/2 phosphorylation was determined in HEK-293T cells transfected with MOR-Rluc cDNA (1.2 g) and Gal1R-YFP cDNA
(2g). A–C, Cells were treated for 12 min with the indicated concentrations of endomorphin-1 (End-1), galanin (Gal), or both. C, Cells were previously incubated for 4 h with MOR TAT-TM1, MOR
TAT-TM5, or MOR TAT-TM7 peptides (4M); top, representative Western blots. Values are expressed as means SEM (n 4–5) of the percentage of values of cells without agonist treatment
(dotted lines). Statistical differences were analyzed by one-way ANOVA followed by Newman–Keuls multiple comparison tests; #p 0.05, ##p 0.01, and ###p 0.001, compared with cells
treated with the same concentration of endomorphin-1 alone.
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cDNA; or a constant amount of serotonin 5HT2B-Rluc receptor
cDNA and increasing amounts of Gal1R-YFP cDNA (Fig. 1C).
These results strongly suggest the specific ability of MOR to het-
eromerize with Gal1R. Further support for the specificity of
MOR–Gal1R heteromerization was obtained by the BiFC assay.
In this assay, two complementary halves of YFP (Venus variant;
cYFP and nYFP) are separately fused to the two putative interact-
ing receptors. Fluorescence is obtained after reconstitution of
functional YFP, when the two receptors come within very close
proximity (Guitart et al., 2014; Bonaventura et al., 2015; Navarro
et al., 2015). Significant fluorescent values could only be detected
in HEK-293T cells cotransfected with Gal1R-cYFP and MOR-
nYFP cDNAs, but not with Gal2R-cYFP and MOR-nYFP (Fig.
1D). Asnegative controls, cellswere transfectedwithnonfused cYFP
andMOR-nYFPorwithGal1R-cYFP andnonfusednYFP (Fig. 1D).
Cotransfection with increasing amounts of nonfused Gal1R pre-
vented complementation of Gal1R-cYFP
withMOR-nYFP and reduced fluorescence
to undetectable values (Fig. 1E), indicating
that MOR–Gal1R heteromerization is not
induced by YFP complementation.
Application of disrupting synthetic pep-
tides fused to the HIV-TAT peptides (see
Materials and Methods), which interact
with the oligomer interface, is providing an
effective tool to dissect the properties of
GPCRheteromers and to demonstrate their
presence in native tissues (He et al., 2011;
Guitart et al., 2014;Bonaventura et al., 2015;
Navarro et al., 2015; Vin˜als et al., 2015). A
TAT peptide with the amino acid sequence
of the transmembrane domain TM1 of the
MOR (MOR TAT-TM1) was used, since it
was previously reported to destabilize het-
eromers of MOR with -opioid receptor
(He et al., 2011). MOR TAT-TM5 and
MORTAT-TM7were also used, since TM5
has been repeatedly reported to be part of
the interface of several GPCR heteromers,
whereas TM7 always provides a negative
control (Guitart et al., 2014; Bonaventura et
al., 2015; Navarro et al., 2015; Vin˜als et al.,
2015). In fact, MOR TAT-TM5, but not
MOR TAT-TM7, significantly prevented
complementation of Gal1R-cYFP with
MOR-nYFP. MOR TAT-TM1 did not sig-
nificantlymodify Gal1R-cYFP-MOR-nYFP
complementation (Fig. 1F). MOR TAT-
peptides were then used as tools to
demonstrate functional properties of the
MOR-Gal1R heteromer in HEK-293T cells
and to demonstrate its presence and func-
tional significance in the VTA.
Functional characteristics of the Gal1R-
MOR
AGPCR heteromer is defined as a macro-
molecular complex composed of at least
two (functional) receptor units (protom-
ers) with biochemical properties that are
demonstrably different from those of its
individual components (Ferre´ et al.,
2009). Among those biochemical proper-
ties, a common consequence of GPCR heteromerization is a spe-
cific integrated signaling after coactivation of the molecularly
different protomers compared with their separate activation
(Ferre´ et al., 2009, 2014; Gomes et al., 2016). In transfected HEK-
293T cells, we evaluated possible interactions between the endog-
enous Gal1R and MOR peptidergic agonists galanin (the 29
amino acid rat sequence; Lang et al., 2015) and endomorphin-1
(Tyr-Pro-Trp-Phe-NH2; Zadina et al., 1997) and the effects of the
peptidergic nonselective Gal1R-Gal2R receptor antagonist M40
(Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-
Pro-Pro-Ala-Leu-Ala-Leu-Ala-NH2; Webling et al., 2012) and
the selective MOR antagonist CTOP (D-Phe-Cys-Tyr-D-Trp-
Orn-Pen-Thr-NH2; Gulya et al., 1988). ERK1/2 phosphorylation
(MAPK activation) was used as the cell signaling output since its
increase in theVTAhas been associatedwith reinforcing effects of
opioids (Hawes et al., 2008). As expected, in cells only transfected
Figure 4. Cross-antagonism within the Gal1R-MOR heteromer. ERK1/2 phosphorylation was determined in HEK-293T cells
transfectedwithMOR-Rluc cDNA (1.2g) and Gal1R-YFP cDNA (2g).A,B, Cells were preincubated for 20minwithmedium, the
MOR antagonist CTOP (10M), or the Gal1R antagonist M40 (10M) and treated for 12min withmedium, galanin (Gal, 100 nM),
or endomorphin-1 (End-1, 100 nM).B, Cellswere previously incubated for 4 hwithMOR TAT-TM1,MOR TAT-TM5, orMOR TAT-TM7
peptides (4M); top, representativeWestern blots. Values are expressed asmeans SEM (n 3–12) of the percentage of values
in untreated cells (dotted lines). Statistical differences were analyzed by one-way ANOVA followed by Newman–Keuls multiple
comparison tests; ***p 0.001, comparedwith untreated cells; ##p 0.01 and ###p 0.001, comparedwith cells treatedwith
the same agonist administered alone.
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with MOR cDNA, endomorphin-1 but not galanin induced
ERK1/2 phosphorylation that was reverted by CTOP but not by
M40 (Fig. 2A). Also as expected, in cells only transfected with
Gal1R cDNA, galanin but not endomorfin-1 induced ERK1/2
phosphorylation that was reverted by M40 but not CTOP (Fig.
2B), which demonstrates the specificity of the ligands for their
respective receptors.
In cells transfected with both MOR and Gal1R, combined ad-
ministration of different concentrations of galanin and endomor-
phin-1 did not produce any additive effect, but the same effect as
galanin alone (Fig. 3A,B).Consequently, galanin significantly coun-
teracted the effect of more effective concentrations of endomor-
phin-1 (Fig. 3A,B). This negative cross talk was blocked by
incubation ofMORTAT-TM5peptide, but notMORTAT-TM1or
MORTAT-TM7(Fig. 3C), demonstrating its dependenceonMOR-
Gal1R heteromerization and, therefore, constituting a biochemical
property of theMOR-Gal1R heteromer. An additional biochemical
property of the MOR-Ga1R heteromers was observed when com-
bining agonists and antagonists. In HEK-293T cells cotransfected
with MOR and Gal1R, the ability of galanin to increase ERK1/2
phosphorylation was not only antagonized by the galanin receptor
antagonist M40, but also by the MOR antagonist CTOP (Fig. 4A).
This cross-antagonism is a property often described for GPCR het-
eromers (Guitart et al., 2014;Bonaventura et al., 2015;Navarro et al.,
2015; Vin˜als et al., 2015). In fact, its dependence on MOR-Gal1R
heteromerization was also demonstrated by its selective blockade
with the MOR TAT-TM5 peptide, but not MOR TAT-TM1 or
MOR TAT-TM7 (Fig. 4B). Cross-antagonism was apparently uni-
directional in transfected cells, and M40 counteracted the effect of
galanin but not endomorphin-1 (Fig. 4A).
Functional Gal1R-MOR heteromers in the VTA locally
modulate ERK1/2, AKT and CREB phosphorylation and
dendritic dopamine release
It has been previously documented from ex vivo experiments that
systemic morphine administration induces ERK1/2 phosphory-
lation (MAPK activation) in the VTA (Valjent et al., 2004; Hawes
et al., 2008), which, however, did not imply a direct activation of
MOR localized in the VTA. To better analyze the role of local
interactions of MOR and galanin receptors within the VTA, we
firstmeasured in situERK1/2 phosphorylation, and alsoAKT and
CREB phosphorylation, in rat VTA slices exposed to selective
ligands (a method previously described by Navarro et al., 2015).
As in previous studies, higher ligand concentrations were used
compared with transfected cell preparations to allow sufficient pen-
etration into the tissue (Bonaventura et al., 2015; Navarro et al.,
Figure5. MAPK activation by Gal1R-MORheteromers in the rat VTA. ERK1/2 phosphorylationwas determined in rat VTA slices pretreated for 3 hwithmedium (A, C) or 4M of theMOR TAT-TM5
peptide or bothMOR TAT-TM1 andMOR TAT-TM7 peptides (B,D). Sliceswere then incubated for 20minwithmedium, theMOR antagonist CTOP (10M), or the Gal1R antagonistM40 (10M) and
treated for 12minwithmedium, galanin (Gal, 1M), endomorphin-1 (End-1, 1M), or both; top, representativeWestern blots. Values are expressed asmeans SEM (3–5 slices) of the percentage
of values in untreated cells (dotted lines). Statistical differenceswere analyzed by one-way ANOVA followed by Newman–Keulsmultiple comparison tests; *p 0.05 and ***p 0.001, compared
with untreated slices; #p 0.05, ##p 0.01, and ###p 0.001, compared with slices only treated with the same concentration of endomorphin-1 or galanin administered alone.
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2015).Endomorfin-1 (1M)produceda significant increase inbasal
ERK1/2 phosphorylation (Fig. 5A). Galanin also produced a signif-
icant increase, although less efficient than endomorphin-1 at the
same concentration (1M; Fig. 5A). On the other hand, coadminis-
tration of endomorphin-1 and galanin did not produce a significant
increase in basal ERK1/2 phosphorylation, indicating a strong and
bidirectional negative cross talk in situ (Fig. 5A). That this negative
cross talk is dependent onMOR–Gal1Rheteromerizationwas dem-
onstrated by the selective blockade with the MOR TAT-TM5 pep-
tide, whereas the combination of both MOR TAT-TM1 plus MOR
TAT-TM7was ineffective (Fig. 5B). Furthermore, theMOR–Gal1R
heteromerization-dependent cross-antagonism observed in trans-
fectedcells couldalsobedemonstrated inratVTAslices.Theeffectof
galanin was completely counteracted by both M40 and CTOP,
whereas that of endomorphin-1 was only significantly counteracted
by CTOP (Fig. 5C). Notably, cross-antagonism of galanin with
CTOPwas selectivelyblockedwith theMORTAT-TM5peptide,but
notwith the combinationof bothMORTAT-TM1plusMORTAT-
TM7 (Fig. 5D).
These results demonstrate that the previously reported ability
of systemic administration of morphine to produce ERK1/2
phosphorylation in the VTA (Valjent et al., 2004; Hawes et al.,
2008) can be related to a direct activation ofMOR in theVTA that
are largely forming heteromers with Gal1R. The possibility of
other signaling pathways mediated by MOR-Gal1R heteromers
in the VTA was also explored in situ by assessing AKT and CREB
phosphorylation in rat VTA slices. To our knowledge, we could
demonstrate for the first time the ability of the local activation of
MORand galanin receptors to induce activation of both signaling
pathways and a strong and bidirectional negative cross talk (Fig.
6). Also, in both cases, a significant cross-antagonism between
galanin andCTOP could be demonstrated (Fig. 6), which implies
the identification of the biochemical properties of the MOR-
Gal1R heteromer.
Finally, we addressed a possible role of MOR-Gal1R hetero-
mers in the modulation of dendritic dopamine release. Dendritic
dopamine release by mesencephalic dopaminergic cells resem-
bles that of the terminal regions, possessing a similar uptake
mechanism and a finite releasable storage
pool (Kita et al., 2009). Furthermore, local
dopamine release in the VTA is a correlate
of dopaminergic cell firing (Legault and
Wise, 1999). For instance, local adminis-
tration of a MOR agonist in the VTA has
been previously shown to increase dopa-
mine release both in the VTA (Chefer et
al., 2009) and in its striatal terminal area,
the nucleus accumbens (Spanagel et al.,
1992). VTA dendritic dopamine release in
vivowas determined with a recently intro-
duced, especially designed infusion–mi-
crodialysis probe that allows the slow
direct infusion of peptides within the
sampling area, which can include pepti-
dergic ligands and disruptive TAT-TM
peptides (Navarro et al., 2015). Using this
technique, we demonstrated the existence
of functional heteromers of orexin and
corticotropin-releasing factor receptors
in the rat VTA (Navarro et al., 2015). As
previously reported for another MOR ag-
onist (DAMGO; Chefer et al., 2009),
intra-VTA infusion of endomorphin-1
(10M) produced a significant dendritic dopamine release (close
to 100% increase in basal extracellular levels; Fig. 7A). Intra-VTA
infusion of galanin (10M) alone did not produce any significant
effect but completely counteracted the effect of endomorphin-1
(Fig. 7A). Synthetic peptides were then used to demonstrate that
these interactions between endomorphin-1 and galanin depend
on MOR-Gal1R heteromers. Intra-VTA infusion of the MOR
TAT-TM5 peptide, but not MOR TAT-TM7 (60 M in both
cases), completely disrupted the ability of galanin to counteract the
dopamine-releasing effect of endomorphin-1 (Fig. 7B). As control
experiments, MOR TAT-TM5 did not modify the basal dopamine
levels or endomorphin-1-induced dopamine release (Fig. 7C).
Discussion
The results of this study demonstrate (1) that MOR can form
heteromers with Gal1R but not with Gal2R, (2) the existence of
functionally significantMOR-Gal1R heteromers in the VTA, and
(3) that this heteromer provides a main mechanism responsible
for opioid–galanin antagonistic interactions. In fact, the results
indicate that dopaminergic cell function in theVTA ismodulated
by a predominant population ofMORs forming heteromers with
Gal1R. Therefore, MOR-Gal1R constitutes an obvious target for
the treatment of opioid use disorders.
The main challenge in the field of GPCR heteromers is the
demonstration of their presence and functional significance in
native tissues and, even more challenging, in vivo. The introduc-
tion of synthetic peptides with the capacity to disrupt the hetero-
mer interface is providing a very valuable tool to determine the
functional characteristics that depend on GPCR heteromeriza-
tion. Sufficient experimental data have now accumulated show-
ing that synthetic peptides with the same amino acid sequence of
the interactive intracellular or TM domains of the different units
(protomers) of GPCR heteromers constitute very selective and
effective tools to disrupt their quaternary structure and, there-
fore, their biochemical properties (Azdad et al., 2009; He et al.,
2011; Guitart et al., 2014; Bonaventura et al., 2015; Navarro et al.,
2015; Vin˜als et al., 2015). Disrupting peptides are first applied in
vitro, using biophysical techniques like BiFC, to visualize their
Figure 6. AKT and CREB phosphorylation by Gal1R-MORheteromers in the rat VTA. AKT (A) and CREB (B) phosphorylationwere
determined in rat VTA slices incubated for 20 min with medium, the MOR antagonist CTOP (10M), or the Gal1R antagonist M40
(10M) and treated for 12 min with medium, galanin (Gal, 1M), endomorphin-1 (End-1, 1M), or both; top, representative
Western blots. Values are expressed as means SEM (3–6 slices) of the percentage of values in untreated cells (dotted lines).
Statistical differences were analyzed by one-way ANOVA followed by Newman–Keuls multiple comparison tests; *p 0.05 and
***p 0.001, compared with untreated slices; #p 0.05 and ###p 0.001, compared with slices only treated with the same
concentration of galanin administered alone.
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ability to significantly distort the quaternary structure of the
GPCRheteromer. Then, their selective ability to disrupt a specific
biochemical effect of ligands binding to either protomer can then
be used as a “biochemical fingerprint” to identify the GPCR het-
eromer in native tissues (Ferre´ et al., 2009). An even more con-
clusive demonstration can be achieved by directly probing the
biochemical property of the heteromer with the in situ or in vivo
application of the specific disruptive peptides.
In the present study, a peptide corresponding to MOR TM5
selectively disrupted MOR–Gal1R heteromerization in BiFC ex-
periments and a negative cross talk at the level of MAPK sign-
aling between the two MOR and Gal1R endogenous ligands
endomorphin-1 and galanin in mammalian transfected cells.
This negative cross talk implied the ability of galanin to counter-
act endomorphin-1-induced ERK1/2 phosphorylation, and its
selective disruption by MOR TM5 implied its dependence on
MOR–Gal1R heteromerization. The presence of functional
MOR-Gal1 heteromers in the VTA could then be demonstrated
by disclosing the same negative cross talk and its selective block-
ade with the MOR TM5 peptide in the native tissue, in rat VTA
slices. MOR-Gal1R heteromers in the VTA therefore provide the
mechanism for the previously described opioid–galanin antago-
nistic interaction on MAPK signaling in the VTA (Hawes et al.,
2008). A further validation of the existence ofMOR-Gal1 hetero-
mers in theVTAwas the demonstration of an additional property
of the heteromer, a cross-antagonism, which constitutes a com-
mon biochemical property of GPCR heteromers (Ferre´ et al.,
2014). The cross-antagonism, which implied the ability of the
MOR antagonist CTOP to block galanin-induced ERK1/2 phos-
phorylation, was present in both transfected cells and in VTA
slices. In both cases, its dependence on MOR–Gal1R heteromer-
ization was demonstrated by its selective blockade with theMOR
TM5 peptide. Furthermore, the same negative cross talk between
endomorphin-1 and galanin and cross-antagonism between
galanin and CTOP could be demonstrated with two additional
signaling pathways, AKT and CREB phosphorylation, wit-
hin the VTA. The complete counteractive effect of galanin on
endomorphin-1-mediated signaling and of CTOP on galanin-
mediated signaling implies that a main population of both MOR
and Gal1R in the VTA are, in fact, forming functional MOR-
Gal1R heteromers.
By applying our recently introduced infusion–microdialysis
probe (Navarro et al., 2015), we could also demonstrate that
MOR-Gal1R heteromers exert a main control of dendritic dopa-
mine release in the VTA, since galanin completely antagonized
endomorphin-1-induced dopamine release and this effect was
selectively counteracted by the MOR TM5 peptide. These results
demonstrate that an integration of opioid and galanin signals by
MOR-Ga1R heteromers in the VTA determines the degree of
activation of the dopaminergic cells. The exact localization of the
heteromers still needs to be determined but could be either in the
terminals of at least one of the main GABAergic afferents already
known to be modulated by MOR, which include afferents from
the striatal patch compartment and from the rostromedial teg-
mental nucleus or tail of the VTA (Barrot et al., 2012; Cui et al.,
2014; Matsui et al., 2014), or in the soma or dendrites of the
dopaminergic cells (Margolis et al., 2014).
The main outcome of the present study is that we have iden-
tified MOR-Gal1R heteromers as a main population of func-
tionalMOR localized in the VTA, whichmodulate dopaminergic
cell activity. This provides a new mechanism by which galanin
influences dopaminergic neurotransmission, adding to other
previously described mechanisms that involve the hypothalamus
Figure 7. Modulation of dendritic dopamine release by Gal1R-MOR heteromers in the
rat VTA. Dopamine (DA) levels in dialysates sampled from the VTA after slow infusion (1
l/h; gray horizontal bar indicates the period of infusion) of endomorphin-1 (End-1, 10
M) and/or galanin (Gal, 10 M) without (A) or with (B, C) infusion (1 l/h; white
horizontal bar indicates the period of infusion) of MOR TAT-TM5 or MOR TAT-TM7 peptides
(60M). Values are means SEM (n 9 –11) and are expressed as percentage of basal
values (average of first 3 values before endomorphin-1 and/or galanin infusion, orexin-A
or CRF infusion). A repeated-measures ANOVA followed by Newman–Keuls multiple com-
parison tests; *p  0.05 and **p  0.01, compared with the last basal values before
endomorphin-1 and/or galanin infusion.
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(paraventricular nucleus), where galanin injections induced ac-
tivation of VTA neurons and dopamine release in the nucleus
accumbens (Rada et al., 1998; Karatayev et al., 2009). The intro-
duction of GPCR heteromers as targets for drug development
provides additional possibilities than just the targeting of one of
the protomers (Ferre´ et al., 2014; Gomes et al., 2016). Therefore,
the MOR-Gal1R heteromer should be viewed as a new target
for the treatment of opioid use disorders. Using Ga1R ligands
should allow a more specific targeting of MOR involved in the
reinforcing effects of opioids. In fact, galanin receptors in the
spinal cord are being considered as targets for pain medications,
with evidence that galanin receptor agonists produce analgesic
effects (Lang et al., 2015). This predicts that coadministration of
MOR and Gal1R agonists can provide strong analgesia with low
addictive consequences. But the significant modulation that the
MOR-Gal1R heteromers exert on the control of dopaminergic
cell function in the VTA could have broader implications for the
treatment of other substance use disorders, as well as other
dopamine-related neuropsychiatric disorders. In fact, there is al-
ready preclinical evidence for the efficacy of the systemic admin-
istration of the nonpeptidergic galanin receptor agonist galnon
on morphine- and also psychostimulant-mediated reinforcing
effects (Hawes et al., 2008; Narasimhaiah et al., 2009; Ogbon-
mwan et al., 2015). In summary, the present results demonstrate
that heteromers of MOR and GalR in the VTA exert a very sig-
nificant modulation of dopamine cell function and, therefore,
these results may represent a significant discovery that provides
the first step toward a clinical application. MOR-GalR1 hetero-
mers in the VTA could constitute important targets for drug
development in substance use disorders and maybe for obesity
secondary to food addiction. The next step could be provided
from additional preclinical experiments that address the long-
term effects of morphine and galanin receptor agonists.
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